You are leaving this website and entering another website. Amgen is not responsible for the content or adopting such content into this website.
A clinical study for men with advanced prostate cancer
The study is testing a new investigational immunotherapy called Xaluritamig for metastatic castration-resistant prostate cancer.
Participants will be in the study for about five years.
Check out our list of frequently asked questions (FAQ).